|Pharmacyclics Announces Updated Results for BTK; ARIAD Offers Data from Pivotal PACE Trial of Ponatinib|
|By Staff and Wire Reports|
|Tuesday, 11 December 2012 20:33|
Pharmacyclics, Inc (Nasdaq: PCYC) and its collaborators provided clinical and pre-clinical presentations on ibrutinib and ibrutinib combinations at the 2012 ASH Annual Meeting. Ibrutinib inhibits Bruton's tyrosine kinase (BTK), which is known to be expressed in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and multiple myeloma (MM). All ASH presentations can be found on the corporate website in the investor relations section.
"This meeting at ASH has been filled with exciting validations of ibrutinib and its potential in blood cancers. We are concluding ASH with 9 poster presentations and 9 oral presentations, of which two were included in the 'ASH Annual Press Program' and both were honored as a 'Best of ASH'," said Bob Duggan, CEO and chairman of Pharmacyclics. "We are very proud of these clinical and research accomplishments and I would like to thank all our investigators and employees for their support and continued efforts in developing this compound for patients in need. Together with our partner Janssen we have now successfully entered several pivotal Phase III trial programs and are broadly developing ibrutinib in a multitude of hematologic cancer settings. The results we have shown over the past couple of days have been very encouraging, demonstrate our commitment to a comprehensive program and we are looking forward to further emerging data in the coming year."
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) announced twelve-month follow-up data from the pivotal PACE trial of ponatinib, its investigational BCR-ABL inhibitor, in heavily pretreated patients with advanced forms of chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study now shows that 57 percent of accelerated-phase CML patients in the trial, including 50 percent of patients with the T315I mutation, achieved a major hematologic response (MaHR), the primary end-point for patients with advanced disease in the trial.
“Patients with advanced forms of Philadelphia chromosome-positive leukemia and those who have failed currently available therapy have limited treatment options available to them,” said Hagop M. Kantarjian, M.D., chairman and professor, Department of Leukemia, University of Texas M.D. Anderson Cancer Center. “The overall prognosis is poor for patients with advanced disease.”
“The pivotal PACE trial data show that ponatinib has robust activity in heavily pretreated patients with accelerated phase CML, more than doubling their reported best prior responses to available TKI therapy,” he added. “What is equally striking is that the median time to achieve a response to ponatinib among accelerated phase patients was only three weeks and that the median duration of major hematologic response in these patients is one year.”
Accelr8 Technology Corporation (NYSE MKT: AXK) will hold its 2012 Annual Meeting of Shareholders (the "Annual Meeting") at 2:30 p.m., local time, on Wednesday, December 12, 2012, at the Warwick Hotel Denver, 1776 Grant Street, Denver, Colorado 80203.
AmbiCom Holdings, Inc. (OTCBB: ABHI), a leading designer and developer of wireless products for the medical industry and a distributor of innovative healthcare products, announced results for its first fiscal quarter.
Diagnostic Imaging International Corp. (OTCQB:DIIG) (PINKSHEETS:DIIG) is pleased to announce that on December 10, 2012, the Company closed the acquisition of Schulkyll Open MRI ("SOMRI").
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and AstraZeneca announced today a strategic alliance for the discovery and development of novel generation antisense therapeutics against five cancer targets, which includes a license to develop and commercialise ISIS-STAT3Rx, a drug Isis is currently evaluating in an early clinical trial in patients with advanced lymphomas.
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the presentation of clinical findings at two medical centers of the successful treatment of brain cancers and tumors using IsoRay's patented Cesium-131 (Cs-131) sutured seeds and seed sutured mesh for internal radiation therapy.
Medicago Inc. (TSX: MDG) (OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has been awarded a non-refundable contribution of up to $493,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).
Medifocus Inc. (TSX VENTURE:MFS) (OTCQX:MDFZF) (Medifocusor the Company) announces that, due to investor demand, it intends to increase the size of the non-brokered private placement of units (the Offering) announced on November 30, 2012.
MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that they will present at the 6th Annual OneMedForum in San Francisco.
Novation Holdings (OTCBB:ALZM) today announced that it has acquired Casita de los Niños, LLC, a California limited liability company doing business as Immersion House™ effective as of November 29, 2012.
Oramed Pharmaceuticals Inc. (OTCBB:ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has completed a capital raise of $4,973,075, net of finder's fee, priced at $0.37 per unit.
Sequenom, Inc. (Nasdaq: SQNM) announced today the appointments of William Welch as the Company's President and Chief Operating Officer and Dirk van den Boom as the Company's Executive Vice President, Research & Development and Chief Technology Officer, both effective immediately.
Sigma-Aldrich Corporation (Nasdaq: SIAL) was recently named to The Civic 50, a national ranking that recognizes the leading community-minded companies in the U.S. Based on a survey conducted by the National Conference on Citizenship (NCoC), a non-profit organization that champions civic leadership, and Points of Light, a non-partisan volunteer organization, The Civic 50 is the first scientific evaluation to rank companies using the criteria of their time, talent and resources to improve the quality of life where they do business.
Syneron Medical Ltd. (NASDAQ: ELOS), http://www.syneron.com, the global leader in medical aesthetic products and technologies, announced the launch of a new Sublative iD™ Focal Tip for challenging treatment areas such as the nasolabial fold ("smile lines") and periorbital rim ("around the eyes").
Z Trim Holdings, Inc. (OTC: ZTHO), a bio-technology company providing value-added ingredients to a variety of industries, announced today that it will begin manufacturing non-GMO corn products in early 2013 to meet expanding domestic and international demand.